IGC Pharma, Inc.

IGC Pharma's capital structure is characterized by a high debt-to-equity ratio of 0.02, indicating minimal leverage. However, the company's liquidity position is weak, with a current ratio of 0.4, suggesting that current liabilities significantly exceed current assets. The company's cash and equivalents have declined from $900,000 at the end of 2025 to $207,000 in Q1 2026, reflecting a net decrease of $693,000. This decline is primarily driven by negative operating cash flow of $1,223,000 and negative free cash flow of $1,224,000. Profitability metrics for IGC Pharma are severely negative. The company reported a net loss of $2,402,000 in Q1 2026, with a return on equity (ROE) of -0.3924 and a return on assets (ROA) of -0.2615. These figures are well below the industry median for pharmaceutical companies, which typically exhibit positive ROE and ROA. The company's operating margin is also negative, with an operating loss of $2,458,000 on revenue of $317,000, indicating significant cost overruns relative to revenue generation. IGC Pharma's revenue is not segmented by geographic region or product line in the provided data, but the company's financial statements indicate a heavy reliance on a limited number of products or markets. The company's cash and equivalents have declined sharply, and the balance sheet shows a significant reduction in accounts receivable and inventory, suggesting potential revenue concentration risks. The company's financial position is further complicated by the need for ongoing capital expenditures, with $1,000 in capital expenditures reported for Q1 2026. The company's growth trajectory is negative, with a net loss of $2,402,000 in Q1 2026 compared to a net loss of $1,198,000 in the same period of 2025. Revenue for Q1 2026 was $317,000, a decline from the $900,000 in cash and equivalents at the end of 2025. The company's financial statements reference going-concern uncertainties, indicating that there is substantial doubt about its ability to continue as a going concern without additional financing. Risk factors for IGC Pharma include high liquidity risk, with current liabilities exceeding current assets, and medium dilution risk, as the company has issued common stock through offerings and has a history of stock-based compensation. The company's financial statements also mention the potential for further dilution through future offerings, which could impact shareholder value. The company's valuation metrics, such as a price-to-book ratio of 5.51 and an enterprise value-to-revenue ratio of 98.65, suggest that the stock is overvalued relative to its financial performance. Recent events for IGC Pharma include the issuance of common stock through offerings, which has increased the number of shares outstanding from 78,203,000 at the end of 2024 to 98,796,089 in Q1 2026. The company has also experienced a decline in cash and equivalents, from $900,000 at the end of 2025 to $207,000 in Q1 2026, reflecting ongoing financial challenges. The company's financial statements reference going-concern uncertainties, indicating that there is substantial doubt about its ability to continue as a going concern without additional financing.